What is Mendor?
Mendor is a Finnish enterprise dedicated to the design, development, and marketing of sophisticated diabetes management products. The company has successfully launched a groundbreaking, user-friendly portable 3G blood glucose meter, complemented by a web-based software application designed for the daily management of diabetes. These products were developed in close collaboration with users and diabetes experts to effectively address the needs of individuals requiring frequent blood glucose monitoring. The company's commitment to innovation in diabetes care positions it as a key player in the health technology market.
How much funding has Mendor raised?
Mendor has raised a total of $145.6M across 4 funding rounds:
Series B
$11.6M
Private Equity
$6.4M
Debt
$8.8M
Private Equity
$118.8M
Series B (2011): $11.6M with participation from Finnvera Venture Capital, Finnish Industry Investment, and Life Sciences Partners
Private Equity (2014): $6.4M led by Life Sciences Partners, Finnish Industry Investment, and Finnvera Venture Capital
Debt (2014): $8.8M supported by IPF Partners
Private Equity (2016): $118.8M featuring IPF Partners and i-SENS Inc
Key Investors in Mendor
IPF Partners
IPF Partners is a prominent alternative financing provider exclusively focused on the healthcare sector, offering tailored debt and equity financing solutions to commercial stage digital health, biopharma, healthcare services, medtech companies, and late-stage biotechs.
i-SENS Inc
i-SENS Inc, known for its CareSens® brand, is a global leader in blood glucose testing, exporting to over 110 countries and holding the number one market share in Korea. They also provide POCT devices and are developing CGM technology.
Life Sciences Partners
Life Sciences Partners (LSP) is a European investment firm specializing in the life sciences sector, providing capital to innovative companies across various stages of development.
What's next for Mendor?
With a substantial total funding amount of $145.6M and a recent strategic investment, Mendor appears to be in a growth phase, likely scaling its operations and expanding its market reach. The company's focus on a critical health need, combined with its technological advancements, suggests a trajectory towards broader adoption of its diabetes management solutions. Future developments may include further product enhancements, strategic partnerships, and international market penetration, leveraging the capital raised to solidify its position in the competitive health tech landscape.
See full Mendor company page
